OTCMKTS:NVTRQ Nuvectra (NVTRQ) Stock Price, News & Analysis → Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad) Free NVTRQ Stock Alerts $0.02 -0.01 (-25.00%) (As of 06/2/2020) Add Compare Share Share Today's Range$0.02▼$0.0250-Day Range$0.0150▼$0.015052-Week Range$0.01▼$4.30Volume382,600 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Nuvectra alerts: Email Address Ad Weiss RatingsWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.I call these Nvidia’s “Silent Partners.” About Nuvectra Stock (OTCMKTS:NVTRQ)Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs. It is also developing Virtis, a sacral neuromodulation (SNM) system for the treatment of chronic urinary retention and overactive bladder; and technologies to support other indications, including SNM for the treatment of overactive bladder and deep brain stimulation to treat Parkinson's disease. The company serves hospitals, surgery centers, and medical facilities through a direct sales force and third-party distributors in the United States and Europe. Nuvectra Corporation was founded in 2008 and is headquartered in Plano, Texas.Read More NVTRQ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVTRQ Stock News HeadlinesAugust 1, 2023 | investing.comImasen Electric Industrial Co Ltd (7266)March 4, 2022 | benzinga.comGlobal Nerve Repair & Regeneration Market (2021 to 2026) - by Product, Application and Geography - Benzin - BenzingaMarch 2, 2022 | businesswire.comOutlook on the Nerve Repair & Regeneration Global Market to 2026 - Featuring Medtronic, Abbott Laboratories and LivaNova Among Others - ResearchAndMarkets.com - Business WireFebruary 17, 2022 | globenewswire.comInteger Holdings Corporation Reports Results for Fourth Quarter and Full Year 2021 - GlobeNewswireFebruary 17, 2022 | stockhouse.comInteger Holdings Corporation Reports Results for Fourth Quarter and Full Year 2021 - StockhouseFebruary 15, 2022 | benzinga.comGlobal Bioelectric Medicine Market (2020 to 2030) - by Product Type, End-user and Region - Benzinga - BenzingaFebruary 8, 2022 | globenewswire.comGlobal Spinal Cord Stimulation Market (2021 to 2026) - by Product, Disease, End-user and Geography - GlobeNewswireDecember 20, 2021 | benzinga.comGlobal Spinal Cord Stimulation Market Research Report 2021 - Benzinga - BenzingaDecember 15, 2021 | streetinsider.comForm DEF 14A MERIDIAN BIOSCIENCE INC For: Jan 26 - StreetInsider.comOctober 28, 2021 | globenewswire.comInteger Holdings Corporation Reports Third Quarter 2021 Results - GlobeNewswireSeptember 17, 2021 | bizjournals.comAfter 3 years without a CEO, Redmond startup Kymeta formalizes leadership structure - Puget Sound Business Journal (Seattle)July 29, 2021 | globenewswire.comInteger Holdings Corporation Reports Second Quarter 2021 Results - GlobeNewswireSee More Headlines Receive NVTRQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvectra and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/29/2018Today5/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolOTCMKTS:NVTRQ Previous SymbolNASDAQ:NVTRV CUSIPN/A CIK1648893 Webwww.nuvectramed.com Phone214-474-3103FaxN/AEmployees197Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Fred B. Parks Ph.D. (Age 72)CEO & Director Mr. Joseph Paul Hanchin (Age 57)Pres Mr. Walter Z. Berger (Age 63)COO, CFO & Exec. VP Ms. Jennifer J. Kosharek (Age 38)VP, Controller & Principal Accounting Officer Mr. Benjamin TranchinaChief Technology OfficerKey CompetitorsAdynxxOTCMKTS:ADYXCalmare TherapeuticsOTCMKTS:CTTCDex LiquidatingOTCMKTS:DXTRQEndologixOTCMKTS:ELGXQLifePointOTCMKTS:LFPIView All Competitors NVTRQ Stock Analysis - Frequently Asked Questions How have NVTRQ shares performed in 2024? Nuvectra's stock was trading at $0.0150 at the beginning of 2024. Since then, NVTRQ stock has increased by 0.0% and is now trading at $0.0150. View the best growth stocks for 2024 here. How were Nuvectra's earnings last quarter? Nuvectra Corp (OTCMKTS:NVTRQ) announced its quarterly earnings data on Monday, October, 29th. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by $0.01. The business earned $14.22 million during the quarter, compared to analysts' expectations of $12.38 million. How do I buy shares of Nuvectra? Shares of NVTRQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:NVTRQ) was last updated on 5/23/2024 by MarketBeat.com Staff From Our PartnersBitcoin’s Biggest Year YetParadigm PressDividend-like income from non-dividend stocksUnstoppable ProsperityWrite this ticker symbol down…StocksToTradeThis could mean the end of the U.S dollar…Colonial MetalsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersGold Set to EXPLODE!Gold Safe Exchange[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectra Corp Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.